Tecentriq and Cellulitis - a phase IV clinical study of FDA data

Summary:

Cellulitis is reported as a side effect among people who take Tecentriq (atezolizumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Avastin, and have Hepatocellular carcinoma.

The phase IV clinical study analyzes which people have Cellulitis when taking Tecentriq. It is created by eHealthMe based on reports of 12,792 people who have side effects when taking Tecentriq from the FDA, and is updated regularly.

What is Tecentriq?

Tecentriq has active ingredients of atezolizumab. eHealthMe is studying from 12,796 Tecentriq users. Check the latest studies of Tecentriq.

What is Cellulitis?

Cellulitis (infection under the skin) is found to be associated with 2,105 drugs and 2,338 conditions by eHealthMe. Check the latest studies of Cellulitis.

On Jul, 14, 2026

12,792 people reported to have side effects when taking Tecentriq.
Among them, 27 people (0.21%) have Cellulitis.

Among these 27 people:

How long have people been on Tecentriq when they have Cellulitis? *

What is the gender of people who have Cellulitis when taking Tecentriq? *

female: 36 %
male: 64 %

What is the age of people who have Cellulitis when taking Tecentriq? *

What are other drugs people take besides Tecentriq? *

What are other side effects people have besides Cellulitis? *

Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 4 people, 14.81%
Rashes (redness): 4 people, 14.81%
Blood Sodium Decreased: 3 people, 11.11%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 3 people, 11.11%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 11.11%
Lower Gastrointestinal Haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding): 3 people, 11.11%
Hepatitis Fulminant (life-threatening condition defined by significantly impaired liver function): 3 people, 11.11%
Brain Natriuretic Peptide Increased: 3 people, 11.11%
Blood Creatinine Increased: 3 people, 11.11%
Eating Disorder: 3 people, 11.11%

What are the existing conditions these people have? *

Hepatocellular Carcinoma (liver cancer): 11 people, 40.74%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 11.11%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 2 people, 7.41%
Lung Cancer - Small Cell (lung cancer): 2 people, 7.41%
Enlarged Prostate: 2 people, 7.41%
Diabetes: 2 people, 7.41%
Arrhythmias (irregular heartbeat): 2 people, 7.41%
Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 1 person, 3.70%
Prostate Cancer: 1 person, 3.70%
Breast Cancer Metastatic: 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Tecentriq and have Cellulitis?

- Check whether Cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tecentriq:

Tecentriq (12,796 reports)

Cellulitis treatments and more:

Cellulitis (75,290 reports)

Browse all side effects of Tecentriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cellulitis:

Cellulitis (2,105 drugs)

Browse all the conditions that are associated with Cellulitis:

Cellulitis (2,338 conditions)

Related publications that referenced our studies

Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .
Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on atezolizumab (the active ingredients of Tecentriq) and Tecentriq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.